MedTrace Logo

A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II

NCT04130191 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 140

Last updated 2025-09-02

No results posted yet for this study

Summary

The main aim of this study is to compare the number of HAE attacks occuring in persons using lanadelumab with the number of HAE attacks before lanadelumab treatment was started.

Data from participants who start the study after 1 March 2021, will be collected for 24 months; data from all other participants (who started the study before 1 March 2021) will be collected for 36 months. Participants will report information in a smartphone application at study start and for the next 3 months and then every 6 months until the study ends; data will also be collected by the study doctor during routine clinic visits

Conditions

  • Hereditary Angioedema (HAE)

Sponsors & Collaborators

  • Takeda Development Center Americas, Inc.

    collaborator INDUSTRY

  • Shire

    lead INDUSTRY

Principal Investigators

  • Study Director · Takeda

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-11
Primary Completion
2024-09-09
Completion
2024-09-09

Countries

  • Austria
  • Germany
  • Israel
  • Italy
  • Kuwait
  • Spain
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04130191 on ClinicalTrials.gov